Abstract
Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic inflammation affecting the colonic mucosa, that can extend to the whole large bowel. The severity of mucosal lesions directly reflects the disease activity and severity and may be prognostic for an aggressive behavior of the pathology. Remission, is usually defined as resolution of symptoms. Recently, mucosal healing (MH) has emerged as an important end point of any shortterm medical therapy for IBD. It may predict long-term remission and may impact on the natural history of the disease in Crohn's disease (CD), while data in UC patients are still limited.
This review of the literature is focused on the recent evidence on the impact of medications on MH in UC and on the impact of MH on the natural course of UC.
Keywords: Ulcerative Colitis, Inflammatory bowel disease, Mucosal healing, Colonoscopy, Medical therapy, MMX, 5-ASA
Current Drug Targets
Title: Mucosal Healing in Ulcerative Colitis: Where do we Stand?
Volume: 12 Issue: 10
Author(s): Gionata Fiorino, Monica Cesarini, Amedeo Indriolo and Alberto Malesci
Affiliation:
Keywords: Ulcerative Colitis, Inflammatory bowel disease, Mucosal healing, Colonoscopy, Medical therapy, MMX, 5-ASA
Abstract: Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic inflammation affecting the colonic mucosa, that can extend to the whole large bowel. The severity of mucosal lesions directly reflects the disease activity and severity and may be prognostic for an aggressive behavior of the pathology. Remission, is usually defined as resolution of symptoms. Recently, mucosal healing (MH) has emerged as an important end point of any shortterm medical therapy for IBD. It may predict long-term remission and may impact on the natural history of the disease in Crohn's disease (CD), while data in UC patients are still limited.
This review of the literature is focused on the recent evidence on the impact of medications on MH in UC and on the impact of MH on the natural course of UC.
Export Options
About this article
Cite this article as:
Fiorino Gionata, Cesarini Monica, Indriolo Amedeo and Malesci Alberto, Mucosal Healing in Ulcerative Colitis: Where do we Stand?, Current Drug Targets 2011; 12 (10) . https://dx.doi.org/10.2174/138945011796818216
DOI https://dx.doi.org/10.2174/138945011796818216 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ligand-Targeted Liposomes for Cancer Treatment
Current Drug Delivery Is Helicobacter pylori Always a "Bad Guy"?
Current Pharmaceutical Design Natural Products as Promising Antitumoral Agents in Breast Cancer: Mechanisms of Action and Molecular Targets.
Mini-Reviews in Medicinal Chemistry Targeted Therapies and other Agents as First-Line Maintenance and Beyond: Particular Benefit in Pulmonary Adenocarcinoma Patients
Current Medicinal Chemistry Milk Fermented with a 15-Lipoxygenase-1-Producing Lactococcus Lactis Alleviates Symptoms of colitis in a Murine Model
Current Pharmaceutical Biotechnology Insights into Angiogenesis in Non-Small Cell Lung Cancer: Molecular Mechanisms, Polymorphic Genes, and Targeted Therapies
Recent Patents on Anti-Cancer Drug Discovery Editorial (Hot Topic: Vitamin D and Cancer: Current Evidence and Future Perspective)
Anti-Cancer Agents in Medicinal Chemistry Anionic Host Defence Peptides from the Plant Kingdom: Their Anticancer Activity and Mechanisms of Action
Protein & Peptide Letters Potential Use of Protease Inhibitors as Vaginal and Colorectal Microbicides
Current HIV Research Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic Agents
Current Cancer Drug Targets LncRNAs: Potential Novel Prognostic and Diagnostic Biomarkers in Colorectal Cancer
Current Medicinal Chemistry Metabolomics: A Revolution for Novel Cancer Marker Identification
Combinatorial Chemistry & High Throughput Screening Enzymes Oxidizing the Azo Dye 1-Phenylazo-2-Naphthol (Sudan I) and their Contribution to its Genotoxicity and Carcinogenicity
Current Drug Metabolism The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets An Augmented Passive Immune Therapy to Treat Fulminant Bacterial Infections
Recent Patents on Anti-Infective Drug Discovery Biosynthetic and Metabolic Alterations in Cancer Growth
Current Angiogenesis (Discontinued) Signal Transduction Inhibitors in the Treatment of Breast Cancer
Current Medicinal Chemistry - Anti-Cancer Agents miRNAs Highlights in Stem and Cancer Cells
Mini-Reviews in Medicinal Chemistry Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer
Current Medicinal Chemistry New Robotic Technologies in Cancer Colon Screening
Clinical Cancer Drugs